Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Avidity Biosciences (RNA) to $70 from $60 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a “notable lengthening” of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences: Promising Advancements and Strategic Positioning Drive Buy Rating
- Avidity Biosciences resumed with a Buy at Goldman Sachs
- Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications
- Lyft upgraded, Block assumed: Wall Street’s top analyst calls
- Avidity Biosciences initiated with an Outperform at Bernstein